MedTrace Logo

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

NCT04454476 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-07-31

No results posted yet for this study

Summary

This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.

Conditions

  • Gastric Cancer
  • Metaplasia
  • Stage I Gastric Cancer
  • Initial-onset Gastric Cancer

Interventions

DRUG

Trametinib treatment

1 mg taken by mouth once a day for 14 days

PROCEDURE

Endoscopy

A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.

Sponsors & Collaborators

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • James Goldenring, MD · Vanderbilt Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2024-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04454476 on ClinicalTrials.gov